Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update

(NASDAQ:CLLS) Cellectis reported financial results for the third quarter of 2026 and provided a business update. As of September 30, 2026, Cellectis had $149 million in consolidated cash, cash equivalents, restricted cash, and fixed-term deposits classified as current and non-current financial assets. Restricted cash totaled $2.3 million, and fixed-term deposits were $118.3 million as of the same date. The company is focusing on its in vivo gene editing pipeline, with .HEAL-101 achieving up to 70% APOC3 gene editing in a humanized liver model and reducing triglycerides by 76% in a disease model after a single administration. The initiation of a Phase 1 investigator-initiated trial for .HEAL-101 in China is on track, with first clinical data expected in the second half of 2027. .HEAL-201 demonstrated more than 90% reduction in mean plasma PCSK9 levels in a liver-humanized mouse model, with a Phase 1 IIT in China planned and preliminary clinical data expected in the first half of 2028. Cellectis is discontinuing the lasme-cel and eti-cel clinical programs, with enrollment stopped and site close-out activities underway. The company expects its global headcount to be reduced by up to 70% from pre-transition levels over 2026 and 2027, subject to French works council consultation and compliance with French and U.S. labor laws. Under its partnership with AstraZeneca, activities continue to develop up to 10 novel cell and gene therapy products. Allogene announced that cema-cel is being evaluated in the ALPHA3 pivotal trial in LBCL, with the next clinical update anticipated in mid-2027 and trial enrollment expected to complete by year-end 2027. Iovance is enrolling patients in a Phase 1/2 trial of IOV-4001 for metastatic melanoma and mNSCLC. As of September 30, 2026, Cellectis' cash position decreased by $62 million from $211 million at December 31, 2025, primarily due to payments to suppliers of $37.9 million, payroll-related payments of $37.5 million, lease liability payments of $7.3 million, repayments of $4.0 million under the PGE loan, and capital expenditures of $1.9 million, partially offset by $21.4 million of cash received from customers and $5.4 million of interest received. Consolidated revenues and other income were $19.9 million for the nine months ended September 30, 2026, compared to $67.4 million for the same period in 2025, a decrease of $47.5 million mainly due to lower activity under the AstraZeneca agreement. R&D expenses were $108.8 million for the nine months ended September 30, 2026, up from $69.1 million in 2025, with a $34.9 million impact from the strategic transformation, including a $26.6 million one-off impairment loss, $6.2 million of termination benefits, and $2.1 million of close-out costs for lasme-cel and eti-cel. SG&A expenses were $17.5 million for the nine months ended September 30, 2026, compared to $15.0 million in 2025, with a $1.1 million impact from the transformation, including $0.9 million of termination benefits and a $0.3 million impairment loss. The consolidated net financial gain for the nine months ended September 30, 2026 was $5.2 million, compared to a $25.6 million net financial loss in 2025, reflecting a $10.8 million increase in financial income and a $20.0 million decrease in financial expenses. Net loss attributable to shareholders was $101.1 million (or $1.00 per share) for the nine months ended September 30, 2026, compared to $41.3 million (or $0.41 per share) in 2025. Adjusted net loss attributable to shareholders was $95.2 million (or $0.95 per share) for the nine months ended September 30, 2026, compared to $37.4 million (or $0.37 per share) in 2025. The company believes its existing cash and equivalents, together with fixed-term deposits, will be sufficient to fund operations into the second half of 2028.

Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026

(NASDAQ:CLLS) Cellectis held its shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4 th floor, 75013 Paris, France. Approximately 55,84% of voting rights were exercised during the meeting. Resolutions 1 through 29 were adopted, while resolution 30 was rejected, consistent with the recommendations of the board of directors. The detailed results of the vote and the resolutions are available on Cellectis’ website: https://www.cellectis.com/en/investors/general-meetings/. Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology and has in-house manufacturing capabilities. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

Cellectis Presents Final Phase 1 Results of Lasme-cel and  Preliminary Results on Eti-cel at EHA 2026 Congress

(NASDAQ:CLLS) Cellectis presented final Phase 1 data from the BALLI-01 clinical trial evaluating lasme-cel, a CD22 directed allogeneic CAR-T therapy, in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), and preliminary data from the NATHALI-01 study evaluating eti-cel, a dual CD20 and CD22 directed CAR-T in relapsed/refractory B-cell non Hodgkin lymphoma (r/r B-NHL), at the European Hematology Association (EHA) 2026 Annual Congress. In the BALLI-01 study, 45 patients in third line and beyond (3L+) were treated, with 15 patients at the recommended Phase 2 dose and 7 in the target Phase 2 population. The target Phase 2 population achieved an overall response rate (ORR) of 100% (7/7) and a complete remission/complete remission with incomplete count recovery (CR/CRi) rate of 57% (4/7), with 75% achieving minimal residual disease negative (MRD-ve) status. Safety data showed cytokine release syndrome (CRS) ≥ grade 3 in 4% of patients, immune effector cell-associated neurotoxicity syndrome (ICANS) ≥ grade 3 in 4%, and immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) ≥ grade 3 in 2%, with all events resolved. In the NATHALI-01 study, as of the February 2026 data cutoff, 14 patients with r/r B-NHL had been treated, with a median of 3 prior lines of therapy, 93% having received prior CD19-directed CAR-T therapy, and all presenting with stage IV disease at baseline; in the optimal dose cohort, ORR and complete response (CR) were 88% and 63%, respectively. The company projects the first interim analysis for the Pivotal Phase 2 BALLI-01 trial in Q4 2026 and expects full Phase 1 clinical data from the NATHALI-01 study in Q4 2026.

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

(NASDAQ:CLLS) Cellectis announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to lasmecabtagene timgedleucel (lasme-cel), its CD22-targeting allogeneic CAR-T cell therapy product candidate, for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The RMAT designation is supported by Phase 1 BALLI-01 data demonstrating promising efficacy and a manageable safety profile. Final Phase 1 data from the BALLI-01 trial of lasme-cel will be presented in an oral session at the 2026 Congress of the European Hematology Association (EHA) on June 13 at 5:15 – 6:30pm CET by Nitin Jain, M.D. The BALLI-01 trial Pivotal Phase 2 is open for enrollment. Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology and controls the cell and gene therapy value chain from start to finish. The company projects the potential of the pivotal Phase 2 BALLI-01 trial to be a registrational phase and the advancement, timing and progress of clinical trials, including with respect to patient enrollment and follow-up.

Cellectis publiera ses résultats financiers du premier trimestre le 11 mai 2026

Cellectis (NASDAQ:CLLS) announced it will publish its financial results for the first quarter ended March 31, 2026, on Monday, May 11, 2026, after the U.S. market close. The press release will be available in the 'Investors' section of the Cellectis website. The company will not hold a conference call to present its results. Cellectis is a clinical-stage biotechnology company developing innovative cell and gene therapies using its genome editing platform. The announcement provides details on how investors can access the results and contact the investor relations team.

Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting

Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company based in France, announced new research on a TALE-based epigenetic editing approach at the American Society of Gene and Cell Therapy (ASGCT) annual meeting. The company developed a high-throughput screening system to rapidly assemble and test hundreds of TALEM proteins, achieving over 90% reduction in gene activity for two distinct genes. The approach does not cut or permanently modify DNA, making it a potentially safer alternative for genome editing. The results demonstrate Cellectis' ability to design potent epigenetic editors across different cell types, enriching its gene-editing toolbox. The poster will be available on Cellectis’ website on May 13, 2026 at 5 pm ET.